Back to Pharma Services
Amicus Therapeutics
Commercial biopharmaceutical company focused on rare genetic lysosomal disorders with approved therapies (Galafold, Pombiliti) and gene therapy collaborations, acquired by BioMarin for $4.8 billion.
Why interesting to a deal team
Regulatory counsel on $4.8B BioMarin acquisition represents deep rare disease M&A strategy expertise. High-value precedent for valuation benchmarking and exit strategy planning in genetic disorders.
Experts connected to this company
Sources
- Structured dataPrimaryamicusrx.com
- No name matchPrimaryir.amicusrx.com
Strongest evidenceStructured data2 public sourcesHow the grades work